FAIM
TMO icon

Financial Advocates Investment Management’s Thermo Fisher Scientific TMO Stock Holding History

Financial Advocates Investment Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,510
Closed -$612K – 547
2025
Q2 		$612K Sell
1,510
-496
-25% -$207K 0.05% 318
2025
Q1 		$998K Sell
2,006
-230
-10% -$125K 0.07% 275
2024
Q4 		$1.16M Sell
2,236
-1,499
-40% -$824K 0.07% 269
2024
Q3 		$2.31M Sell
3,735
-15
-0.4% -$8.88K 0.13% 164
2024
Q2 		$2.07M Sell
3,750
-475
-11% -$272K 0.13% 168
2024
Q1 		$2.46M Buy
4,225
+118
+3% +$66.2K 0.14% 160
2023
Q4 		$2.18M Buy
4,107
+204
+5% +$98.7K 0.14% 163
2023
Q3 		$1.98M Buy
3,903
+14
+0.4% +$7.46K 0.14% 165
2023
Q2 		$2.03M Sell
3,889
-68
-2% -$36.7K 0.14% 161
2023
Q1 		$2.28M Buy
3,957
+606
+18% +$342K 0.16% 146
2022
Q4 		$1.85M Buy
3,351
+63
+2% +$33.4K 0.14% 175
2022
Q3 		$1.67M Buy
3,288
+287
+10% +$161K 0.14% 170
2022
Q2 		$1.63M Buy
3,001
+582
+24% +$320K 0.13% 192
2022
Q1 		$1.43M Buy
2,419
+176
+8% +$101K 0.09% 236
2021
Q4 		$1.5M Sell
2,243
-18
-0.8% -$11.2K 0.09% 250
2021
Q3 		$1.33M Sell
2,261
-3,688
-62% -$2.02M 0.09% 255
2021
Q2 		$1.09M Buy
5,949
+3,112
+110% +$1.47M 0.07% 298
2021
Q1 		$1.29M Buy
2,837
+45
+2% +$21.5K 0.09% 257
2020
Q4 		$1.3M Buy
2,792
+104
+4% +$48.8K 0.09% 256
2020
Q3 		$1.19M Sell
2,688
-34
-1% -$14K 0.1% 214
2020
Q2 		$986K Buy
2,722
+53
+2% +$17.8K 0.09% 251
2020
Q1 		$757K Buy
2,669
+402
+18% +$127K 0.11% 217
2019
Q4 		$736K Buy
2,267
+562
+33% +$170K 0.08% 249
2019
Q3 		$496K Buy
1,705
+3
+0.2% +$859 0.06% 287
2019
Q2 		$500K Buy
1,702
+84
+5% +$23.1K 0.06% 293
2019
Q1 		$443K Sell
1,618
-39
-2% -$9.71K 0.06% 294
2018
Q4 		$371K Sell
1,657
-307
-16% -$72K 0.05% 295
2018
Q3 		$479K Buy
1,964
+51
+3% +$11.7K 0.05% 293
2018
Q2 		$393K Sell
1,913
-230
-11% -$48.8K 0.05% 309
2018
Q1 		$442K Buy
2,143
+13
+0.6% +$2.73K 0.06% 281
2017
Q4 		$404K Buy
+2,130
New +$408K 0.06% 291

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Financial Advocates Investment Management's TMO Position: Q3 2025 in Review

Financial Advocates Investment Management sold out of Thermo Fisher Scientific (TMO) in Q3 2025, closing a stake of 1,510 shares — an estimated $612K sold.

Financial Advocates Investment Management first reported a position in TMO in Q4 2017 and held it in 31 quarters. The position peaked at $2.46M in Q1 2024. 2,510 funds tracked by Wall St. Rank hold TMO as of Q3 2025.

  • Financial Advocates Investment Management reported no remaining Thermo Fisher Scientific position as of Q3 2025 after selling out during the quarter.
  • Financial Advocates Investment Management sold 1,510 Thermo Fisher Scientific shares in Q3 2025, an estimated $612K.
  • Financial Advocates Investment Management first reported a position in Thermo Fisher Scientific in Q4 2017 and held it in 31 quarters.
  • Financial Advocates Investment Management's Thermo Fisher Scientific position peaked at $2.46M in Q1 2024.
  • 2,510 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2025.

Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.